Grail released new PATHFINDER study results showing improved positive predictive value for its multi‑cancer Galleri blood test, findings that company executives argue strengthen its case for broader clinical rollout. The large U.S. PATHFINDER‑2 cohort (nearly 36,000 adults age ≥50) delivered a sensitivity of 40.4% with a higher proportion of early‑stage detections for cancers not covered by standard screening. STAT’s coverage noted the test’s positive predictive value rose to about 62% among participants with a positive test, an improvement versus earlier studies but still leaving a substantial false‑positive fraction. Grail positioned the data as evidence of technical progress as it approaches regulatory filings. For clinicians and lab directors: the updated performance metrics will shape discussions with regulators, payers, and screening programs about clinical utility, downstream diagnostic pathways, and the test’s role alongside conventional screening modalities.